Pregnancy Label Due Date Approaching? Risk, Clinical Info Could Be Split
Executive Summary
FDA is seeking to move ahead quickly with new regulations for pregnancy labeling following the release of the physician labeling final rule
You may also be interested in...
FDA “Xes” Letter Categories For Pregnancy Labels; Data Collection Drives Reg
FDA's proposed rule to update the format of the pregnancy and lactation sections of drug labeling does not require the firms collect new data about their products, but the agency is hoping to use various mechanisms to encourage them to do so
FDA “Xes” Letter Categories For Pregnancy Labels; Data Collection Drives Reg
FDA's proposed rule to update the format of the pregnancy and lactation sections of drug labeling does not require the firms collect new data about their products, but the agency is hoping to use various mechanisms to encourage them to do so
Early Pregnancy Safety Concerns With ACE Inhibitors Could Affect ARBs
Concerns about exposure to angiotensin-converting enzyme inhibitors during the first trimester of pregnancy could have consequences for other classes of antihypertensives, including angiotensin II receptor blockers